Impact of HER2 on prognosis and benefit from adjuvant chemotherapy in stage II/III gastric cancer patients: a multicenter observational study.

Xianchun Gao Lulu Zhao Nannan Zhang Weili Han Kun LiuJunya YanLing ChenYan PanRenlong LiWenjiao LiHaohao ZhangHongwei LiShibo WangXiaoliang GaoPenghui NiuWanqing WangGang JiQingchuan ZhaoYuanyuan LuZengshan LiLei ShangHan LiangKaichun Wu Jingyu Deng Yingtai Chen Yongzhan Nienull null

Published in: International journal of surgery (London, England) (2023)

Fluorouracil-based adjuvant chemotherapy is insufficient for stage II GC patients with high HER2 expression, indicating that prospective trials are required to validate alternative HER2-targeted adjuvant therapies in the individuals above.

Keyphrases

end stage renal disease
newly diagnosed
chronic kidney disease
poor prognosis
early stage
ejection fraction
prognostic factors
patient reported outcomes
peritoneal dialysis
high resolution
mass spectrometry
drug delivery
simultaneous determination